Oren Livne

Oren Livne

Baker & McKenzie LLP


Oren Livne is a partner in the Corporate & Securities Practice Group and the Life Sciences Industry Group. Before beginning his legal career, Oren co-founded a university technology transfer office and managed its licensing operations, which, together with his M.B.A, from New York University's Leonard N. Stern School of Business, provide a unique business perspective that he leverages for the benefit of the firm's clients.

Practice Focus

Oren Livne counsels clients from startups to multinationals on a variety of corporate and transactional matters globally, including complex license and collaboration agreements, joint ventures, spin outs, commercial contracts, mergers and acquisitions, and other intellectual property focused transactions. His clients include pharmaceutical, biotech, medical device, consumer product, and technology companies as well as private equity firms. Oren is a guest lecturer at New York University law and business classes and has authored several licensing and intellectual property articles.

Representative Legal Matters

  • Merck in its collaboration and option agreement with ONSSI. 

  • Bayer in its acquisition of drug discovery company Vividion Therapeutics for USD 1.5 billion upfront and up to USD 500 million in success-based milestone payments.

  • Astellas in its license agreement with ExCellThera for the in vitro use of certain molecules in the field of pluripotent stem cells (PSCs) and PSC-derived cells.

  • MIMETAS in its collaboration with Roche to develop human disease models for drug development.

  • CytoSorbents in its global co-marketing agreement with B. Braun to promote the OMNI® continuous blood purification platform with CytoSorb®.

  • MyoKardia, a wholly-owned subsidiary of Bristol Myers Squibb, in its research collaboration with Avidity Biosciences to demonstrate the potential utility of AOCs in cardiac tissue.

  • argenx in its strategic collaboration for efgartigimod in greater China, including USD 75 million in upfront Zai Lab equity and USD 100 million in near-term milestone and other payments.

  • Abbott in its agreement with eMed for the delivery and administration of Abbott's BinaxNOW™ COVID-19 test for virtually guided at-home use.

  • Galapagos in its new commercialization and development agreement with Gilead for Jyseleca® (filgotinib) under which Galapagos assumes sole responsibility for Europe

  • Abbott in its collaboration with Supersapiens to advance Abbott's Libre Sense Glucose Sport Biosensor, which is designed to help athletes better understand the correlation between their glucose levels and their athletic performance.

Professional Honors

  • Life Sciences Star, Licensing & Collaboration, LMG Life Sciences, 2021
  • Shortlisted for Innovative Lawyers Award Asia-Pacific, Practice of Law - Healthcare, to Baker McKenzie Healthcare & Life Sciences Group on COVID-19 Response, FT 2021 
  • IFLR Europe M&A Deal of the Year 2020, European Lifestars Deal of the Year 2019 (> GBP 500 million), and Best M&A Award Large-Cap Corporate Deal 2019 (Belgium) for the Galapagos - Gilead collaboration 
  • Dealmakers Award to Baker McKenzie Life Sciences Group, NJLJ Professional Excellence, 2020
  • Notable Practitioner, IFLR 1000, 2020
  • Rising Star, Super Lawyers New Jersey, 2020-2021
  • Rising Star, Healthcare: Life Sciences, The Legal 500 United States, 2019
  • Certified Licensing Professional, 2008-2023

Professional Associations and Memberships

  • New York State Bar Association
  • New Jersey State Bar Association
  • Licensing Executives Society


  • New York~United States
  • New Jersey~United States
  • U.S. Patent and Trademark Office~United States


  • New York University (MBA, with distinction) (2012)
  • New York University School of Law (JD) (2012)
  • Rutgers University (BS Chemical Engineering, with Highest Honors) (1996)


  • English